Man, this sure is not turning into one of those “nothing to see here” columns.
No sir, the 12 months that have passed since we last sat down together to review the state of anti-inflammation treatment in dry eye disease (DED) have been tumultuous, to say the least. Yes ma’am, I am planning to review the whole mess for you all out there in Eyeland. After doing that, I may have a thought or two about what is on the way and how we may collectively be able to turn (Read more...)